Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.96 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.96 |
| ▸ | HPGD | P15428 | 7/20 | 0.96 |
| ▸ | ESR1 | P03372 | 1/20 | 0.96 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.96 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.96 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | GGT1 | P19440 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL10456693 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL1331740 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL29350479 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL7580 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL1353 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL21488922 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL21722099 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL4391645 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL21328429 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL20484785 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164871-A | N-ester-2-acetylsalicylamide compound and preparation method and application thereof | 湖南科技大学 | 2024-06-11 | — | — | CN | claimed |
| CN-115154401-B | Anti-inflammatory and soothing emulsion and preparation method thereof | 武汉诺安药业有限公司 | 2023-10-10 | — | — | CN | claimed |
| WO-2023129116-A2 | A DRUG FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS DISEASE AND THE NANOPARTICLE THEREOF | GAZIANTEP UNIVERSITESI REKTORLUGU (TR) | 2023-07-06 | — | — | WO | claimed |
| CN-114478297-A | Synthetic preparation method of paracetamol | 山东省科学院菏泽分院 | 2022-05-13 | — | — | CN | claimed |
| CN-113564122-A | Method for differentiating human induced pluripotent stem cells into oligodendrocytes, kit and application | 呈诺再生医学科技(珠海横琴新区)有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-108129468-B | Aspirin derivatives and preparation method and application thereof | 四川理工学院 | 2020-09-29 | — | — | CN | claimed |
| CN-111417730-A | Diagnostic method | 托雷莫治疗股份公司 | 2020-07-14 | — | — | CN | claimed |
| CN-110668947-A | O-hydroxybenzoic acid polyglycol ester compound and synthesis preparation method and medical application thereof | 新乡海盈生物科技有限责任公司 | 2020-01-10 | — | — | CN | claimed |
| CN-109651184-A | A kind of benorylate synthesis technology | 张洪迎 | 2019-04-19 | — | — | CN | claimed |
| JP-5086048-A | — | — | None | — | — | JP | disclosed |
| CN-119591657-B | Cyclovirobuxine D derivative, and preparation method and application thereof | 中国药科大学 | 2026-05-22 | — | — | CN | disclosed |
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS INC. (JP) | 2025-03-27 | — | — | US | disclosed |
| CN-119591657-A | Cyclovirobuxine D derivative, and preparation method and application thereof | 中国药科大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-118403070-A | Heparin-aspirin compound, preparation and application | 中国科学院理化技术研究所 | 2024-07-30 | — | — | CN | disclosed |
| US-4072753-A | DERMATITIS, MULTIPLE SCLEROSIS, BENZANILIDES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1978-02-07 | — | — | US | disclosed |
| US-4032635-A | BENZANILIDE DERIVATIVES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-06-28 | — | — | US | disclosed |
| US-4014921-A | ANALGESICS, ANTIPYRETIC, ANTIINFLAMMATORY | ALTER, S.A. (ES) | 1977-03-29 | — | — | US | disclosed |
| US-4006181-A | Process for the obtaining of esters of acetylsalicylic acid and amino alcohols | PIERRE FABRE S.A. (FR) | 1977-02-01 | — | — | US | disclosed |
| US-3940407-A | β-Adrenergic blocking agents in the 1,2,3-thiadiazole series | SYNTEX (U.S.A.) INC. (US) | 1976-02-24 | — | — | US | disclosed |
| US-3935214-A | ANTICOAGULANT | DONAU-PHARMAZIE GESELLSCHAFT M.B.H. (OE) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | PTGS1, PTGIS, PTGS2 | PTGS1 1/4885PTGS2 3/4885KDM4E 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.